title: Pre-operative redox state affects 1-month survival in patients with advanced heart failure undergoing left ventricular assist device implantation.
abstract: BACKGROUND
  Left ventricular assist device (LVAD) implantation has proven effective as a bridge to transplantation in end-stage heart failure patients (ESHFPs), although survival during device support is critical. Oxidative stress has been implicated in the development of heart failure, but the influence of redox state on in-hospital post-LVAD outcome has not been clarified.
  
  
  RESULTS
  In this report we describe the oxidant/anti-oxidant profiles of 15 ESHFPs before LVAD placement, 5 of whom did not survive to 1 month, and in 30 subjects without cardiac disease, representing the control group.
  
  
  CONCLUSIONS
  Preliminary findings suggest that adequate activity of the GPx-1-based anti-oxidant system before device placement is associated with patient survival up to 1 month, despite comparable baseline oxidative stress in patients who both survived and died (within 2 weeks post-LVAD).
authors.affiliation: CNR Clinical Physiology Institute of Milan, Milan, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Caruso
authors.forename: Andrea
authors.initials: A
authors.lastname: Garatti
authors.forename: Valentina
authors.initials: V
authors.lastname: Sedda
authors.forename: Filippo
authors.initials: F
authors.lastname: Milazzo
authors.forename: Jonica
authors.initials: J
authors.lastname: Campolo
authors.forename: Tiziano
authors.initials: T
authors.lastname: Colombo
authors.forename: Emanuele
authors.initials: E
authors.lastname: Catena
authors.forename: Giuliana
authors.initials: G
authors.lastname: Cighetti
authors.forename: Claudio
authors.initials: C
authors.lastname: Russo
authors.forename: Maria
authors.initials: M
authors.lastname: Frigerio
authors.forename: Ettore
authors.initials: E
authors.lastname: Vitali
authors.forename: Oberdan
authors.initials: O
authors.lastname: Parodi
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D005978:Glutathione / Q000097:blood; D005979:Glutathione Peroxidase / Q000097:blood; D005980:Glutathione Reductase / Q000097:blood; D006333:Heart Failure / Q000378:metabolism* / Q000628:therapy*; D006352:Heart Ventricles / Q000503:physiopathology*; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000502:physiology; D011237:Predictive Value of Tests; D016019:Survival Analysis; D016896:Treatment Outcome; D000094765:Glutathione Peroxidase GPX1
chemical_list: D015415:Biomarkers; D008315:Malondialdehyde; C486484:GPX3 protein, human; D005979:Glutathione Peroxidase; D005980:Glutathione Reductase; D005978:Glutathione; D000094765:Glutathione Peroxidase GPX1; C000722067:GPX1 protein, human